Institution Directory

Clinical trials at Mount Sinai

Sites in New York, NY

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 10:22 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1100

Shown on this page

Current sort

Live official records

Conditions: Peripartum Cardiomyopathy, Postpartum
Interventions: Bromocriptine, Placebo, Guideline Directed Medical Therapy for Heart Failure (GDMT), Rivaroxaban, Second Placebo; Drug
Lead sponsor: Dennis M. McNamara, MD, MS; Other
Eligibility: 18 Years and older · Female only
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 64
States / cities: Birmingham, Alabama • Tucson, Arizona • La Jolla, California + 51 more

Conditions: Type 2 Diabetes, Steroid-induced Diabetes
Interventions: Libre 3 Plus continuous glucose monitoring (CGM) system, Blinded Continuous Glucose Monitoring, Finger stick; Device · Behavioral
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Early Alzheimer's Disease
Interventions: CT1812, Placebo; Drug
Lead sponsor: Cognition Therapeutics; Industry
Eligibility: 50 Years to 85 Years
Enrollment: 540 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 50
States / cities: Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 41 more

Conditions: Homocystinuria
Interventions: Pegtibatinase, Placebo; Drug
Lead sponsor: Travere Therapeutics, Inc.; Industry
Eligibility: 5 Years to 65 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 10
States / cities: Aurora, Colorado • Miami, Florida • Chicago, Illinois + 6 more

Conditions: Multiple Myeloma
Interventions: Not listed
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 3
States / cities: San Francisco, California • New York, New York

Conditions: Sustained VT
Interventions: cryoablation procedure; Device
Lead sponsor: Adagio Medical; Industry
Eligibility: 18 Years and older
Enrollment: 206 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 13
States / cities: Phoenix, Arizona • San Francisco, California • Baltimore, Maryland + 9 more

Conditions: Melanocortin Obesity Syndrome, MCOS
Interventions: Atomoxetine, Placebo; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 6 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 3
States / cities: New York, New York • Columbus, Ohio • Nashville, Tennessee

Conditions: Intracerebral Hemorrhage, Stroke, Hypertension
Interventions: Clevidipine Injection, Alternate IV Antihypertensive Regimen; Drug
Lead sponsor: Zeenat Qureshi Stroke Institute; Other
Eligibility: 18 Years to 100 Years
Enrollment: 1,018 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 20
States / cities: Irvine, California • Lancaster, California • Palo Alto, California + 17 more

Conditions: Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma, Fallopian Tube Malignant Mixed Mesodermal (Mullerian) Tumor, FIGO Stage III Ovarian Cancer 2014, FIGO Stage IV Ovarian Cancer 2014, Ovarian Carcinoma, Ovarian Carcinosarcoma, Ovarian High Grade Endometrioid Adenocarcinoma, Ovarian High Grade Serous Adenocarcinoma, Primary Peritoneal Carcinosarcoma, Primary Peritoneal Endometrioid Adenocarcinoma, Primary Peritoneal High Grade Serous Adenocarcinoma
Interventions: Bevacizumab, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Olaparib; Biological · Procedure · Drug
Lead sponsor: NRG Oncology; Other
Eligibility: 18 Years and older
Enrollment: 880 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2034
U.S. locations: 676
States / cities: Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 458 more

Conditions: Acute Erythroid Leukemia, Acute Megakaryoblastic Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Myelodysplastic Syndrome With Excess Blasts, Myelodysplastic Syndrome With Ring Sideroblasts, Recurrent Adult Acute Myeloid Leukemia, Refractory Anemia
Interventions: Azacitidine, Laboratory Biomarker Analysis, Pharmacological Study, Vorinostat; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2026
U.S. locations: 7
States / cities: Chicago, Illinois • Baltimore, Maryland • Manhasset, New York + 2 more

Conditions: Ovarian Carcinoma
Interventions: Bilateral Salpingectomy, Bilateral Salpingectomy with Oophorectomy, Biospecimen Collection, Magnetic Resonance Imaging, Quality-of-Life Assessment, Questionnaire Administration, Transvaginal Ultrasound, Ultrasound Imaging; Procedure · Other
Lead sponsor: NRG Oncology; Other
Eligibility: 35 Years to 50 Years · Female only
Enrollment: 1,956 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2047
U.S. locations: 564
States / cities: Birmingham, Alabama • Anchorage, Alaska • Goodyear, Arizona + 372 more

Conditions: Phelan-McDermid Syndrome, Autism Spectrum Disorder, Intellectual Disability
Interventions: Not listed
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 18 Months and older
Enrollment: 207 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2026
U.S. locations: 5
States / cities: Stanford, California • Chicago, Illinois • Bethesda, Maryland + 2 more

About this Mount Sinai institution page

What this page lists: ClinicalTrials.gov records that list Mount Sinai in New York, NY as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status: A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Clinical trials at Mount Sinai

Filter and sort this campus

Live official records

Impact of Bromocriptine on Clinical Outcomes for Peripartum Cardiomyopathy

CGM After Discharge From Hospital

A Study to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease

Pegtibatinase as a Treatment for Patients With Classical Homocystinuria (HCU) (Also Known as the COMPOSE Study)

Delayed Toxicities Post-CAR-T

Cryoablation for Monomorphic Ventricular Tachycardia

Atomoxetine in Melanocortin Obesity Syndrome

Clevidipine for the Antihypertensive Treatment of Acute Intracerebral Hemorrhage

Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer

Vorinostat and Azacitidine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia

A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer

Mapping the Genotype, Phenotype, and Natural History of Phelan-McDermid Syndrome

About this Mount Sinai institution page